

Applicant: Graham P. Allaway et al.
U.S. Serial No.: 09/888,938
Filed: June 25, 2001
Page 3

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the specification:

Listing of Claims:

1-50. (Canceled)

51. (Currently Amended) An isolated antibody ~~or portion of an antibody~~ capable of binding to a human chemokine receptor on the surface of a CD4+ cell and inhibiting HIV-1 infection of such CD4+ cell.
52. (Currently Amended) The antibody ~~or portion of an antibody~~ capable of binding to a CCR5 chemokine receptor on the surface of a CD4+ cell of claim 1, wherein the chemokine receptor is a CCR5 receptor.
53. (Currently Amended) The antibody ~~or portion of an antibody~~ of claim 51 or 52, wherein the CD4+ cell is a PM-1 cell.
54. (Currently Amended) The antibody ~~or portion of an antibody~~ of claim 51 or 52, wherein the CD4+ cell is a primary CD4+ T-cell.
55. (Currently Amended) The antibody ~~or portion of an antibody~~ of claim 51 or 52, wherein the CD4+ cell is a peripheral blood mononuclear cell (PBMC) ~~(PMBC) cell~~.
56. (Currently Amended) The antibody ~~or portion of an antibody~~ of claim 51 or 52, wherein the antibody is a monoclonal antibody.

Applicant: Graham P. Allaway et al.
U.S. Serial No.: 09/888,938
Filed: June 25, 2001
Page 4

57. (New) A pharmaceutical composition comprising the antibody any of claims 51, 52 or 56 and a pharmaceutically acceptable carrier.
58. (New) The pharmaceutical composition of claim 57, wherein the antibody is present in an amount effective to inhibit HIV-1 infection.